Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Bacil Pharma Ltd has submitted to BSE the newspaper clipping of its audited financial results for the quarter and full year ended March 31, 2026, as required under SEBI (LODR) Regulation 47(1)(b). The results were published in Financial Express (English) and a Marathi newspaper on June 3, 2026. Key numbers from the published table: total income from operations stood at ₹11.34 lakh in Q4 FY26 (vs ₹66.14 lakh in Q4 FY25) and ₹123.52 lakh for full year FY26 (vs ₹198.50 lakh in FY25). Net profit after tax for Q4 FY26 was ₹62.16 lakh, while full-year FY26 PAT came in at ₹155.55 lakh, a turnaround from a loss of ₹6.17 lakh in FY25. Equity share capital remained unchanged at ₹1,397.03 lakh, with basic EPS of ₹1.11 for FY26.
This is primarily a procedural compliance filing, not a new event. However, the underlying numbers show the company swung to a full-year profit in FY26 after a loss the previous year, even as annual revenue declined — a mixed signal worth noting. No immediate price catalyst is expected from the filing itself.